Recent advances in the status and targets of antithrombotic agents

Drugs of the Future

Volumn 27, Issue 7, 2002, Pages 669-683

  Raghavan, S A V ^a   Dikshit, M ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; 4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTICOAGULANT AGENT; APROSULATE; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CAMONAGREL; DESULFATOHIRUDIN; EFEGATRAN; ENOXAPARIN; FOROPAFANT; FRADAFIBAN; HIRUDIN; HIRULOG; IFETROBAN; LEFRADAFIBAN; LIPOPROSTAGLANDIN E1; MELAGATRAN; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; PROUROKINASE; ROXIFIBAN; SIBRAFIBAN; THROMBIN INHIBITOR; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; TINZAPARIN; UNINDEXED DRUG; YM 337;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; INDUCED HYPOTENSION; ISCHEMIA; REVIEW; THROMBOEMBOLISM; THROMBOSIS;

EID: 0036660418     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.07.691715     Document Type: Review

References (120)

1. Bornstein, N.M. Antiplatelet agents: How to select them and the possibility of combined treatment. Cerebrovasc Dis 2001, 11: 96-9.
2. Chackalamannil, S. Thrombin receptor antagonists as novel therapeutic targets. Curr Opin Drug Discov Dev 2001, 4: 417-27.
3. Von dem Borne, P.A., Bajzar, L., Meijers, J.C. et al. Thrombin-mediated activation of factor XI results in thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997, 99: 2323-7.
4. Collen, D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999, 82: 259-70.
5. Mayer, M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 1990, 23: 197-211.
6. Weitz, J. New anticoagulant strategies. Drugs 1994, 48: 485-97.
7. Heines, S.T., Bussey, H.I. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995, 29: 892-905.
8. Ginsberg, J.S. Management of venous thromboembolism. N Engl J Med 1996, 335: 1821-8.
9. Hirsh, J. Low molecular weight heparin: A review of the results of recent studies of the treatment of venous thrombolism and unstable angina. Circulation 1998, 98: 1575-82.
10. Antman, E.M., McCabe, C.H., Gurfinkel, E.P. et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non Q-wave myocardial infarction. Circulation 1999, 100: 1593-601.
11. Wu, Q., Sheehan, J.P., Tsiang, M. et al. Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin- binding activities of human thrombin. Proc Natl Acad Sci USA 1991, 88: 6775-9.
12. Menear, K. Direct thrombin inhibitors: Current status and future prospects. Exp Opin Invest Drugs 1999, 8: 1373-84.
13. Andersen, K., Dellborg, M. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) study group. Am J Cardiol 1998, 81: 939-44.
14. Tsiang, M., Jain, A.K., Dunn, K.E. et al. Functional mapping of the surface residues of human thrombin. J Biol Chem 1995, 270: 16854-63.
15. Schror, K. Antiplatelet drugs: A comparative review. Drugs 1995, 50: 1-28.
16. Markwardt, F. The development of hirudin as an antithrombotic drug. Thromb Res 1994, 74: 1-23.
17. Greinacher, A., Volpel, H., Janssens, U. et al. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999, 99: 73-80.
18. Matsuo, T., Koide, M., Kario, K. Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin Thromb Hemost 1997, 23: 517-22.
19. Berry, C.N., Girard, D., Lochot, S., Lacolira, C. Antithrombotic actions of argatroban in rat models of venous, "mixed" and arterial thrombosis and its effects on the tail transection bleeding time. Br J Pharmacol 1994, 113: 1209-14.
20. Hantgan, R. R., Jerome, W.G., Hursting, M.J. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 1998, 92: 2064-72.
21. McKeage, K., Plosker, G.L. Argatroban. Drugs 2001, 61: 515-22.
22. Serebruany, V.L., Jang, I.K., Giugliano, R.P., et al. A randomized blinded study of two doses of Novastan(R) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan® and t-PA (MINT) study. J Thromb Thrombolysis 1998, 5: 49-52.
23. Catella-Lawson, F. Direct thrombin inhibitors in cardiovascular disease. Coron Artery Dis 1997, 8: 105-11.
24. Lefkovits, J., Topol, E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994, 901: 1522-36.
25. DiMaio, J., Gibbs, B., Munn, D. et al. Bifunctional thrombin inhibitors based on the sequence of hirudin 45-65. J Biol Chem 1990, 265: 21698-703.
26. Leblond, L., Grouix, B., Boudreau, C. et al. In vitro and in vivo properties of bicyclic lactam inhibitors: A novel class of low molecular weight peptidomimetic thrombin inhibitors. Thromb Res 2000, 100: 195-209.
27. Lauwereys, M., Stanssens, P., Lambeir, A.M. et al. Ecotin as a potent factor Xa inhibitor. Thromb Haemost 1993, 69: 783.
28. Lewis, S.D., Ng, A.S., Lyle, E.A. et al. Inhibition of thrombin by peptides containing lysyl-α-ketocarbonyl derivatives. Thromb Haemost 1995, 74: 1107-12.
29. Eriksson, B.I., Carlsson, S., Halvarsson, M. et al. Antithrombotic effect of two low-molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997, 78: 1404-7.
30. Eriksson, H., Eriksson, U.G., Frison, L. et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999, 81: 358-63.
31. Hall, S.W., Gibbs, C.S., Leung, L.L.K. Strategies for development of novel antithrombotics: Modulating thrombin's procoagulant and anticoagulant properties. Cell Mol Life Sci 1997, 53: 731-6.
32. Esmon, C.T., Taylor, F.B., Snow, T.B. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991, 66: 160-5.
33. Aoki, Y., Fukumoto, Y., Inoue, K. et al. Effect of activated human protein C on experimental venous thrombosis induced by stasis with operative invasion in mice. Arzneim-Forsch 2000, 50: 695-9.
34. Dang, Q.D., Vindigni, A., Di Cera, E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci USA 1995, 92: 5977-81.
35. Zhang, H.C., Derian, C.K., Andrade-Gordon, P. et al. Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: Potent, selective peptide mimetics based on indole and indazole templates. J Med Chem 2001, 44: 1021-4.
36. Harker, L.A., Hanson, S.R., Kelly, A.B. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997, 78: 736-41.
37. Fevig, J.M., Wexler, R.R. Anticoagulants: Thrombin and factor Xa inhibitors. Ann Rep Med Chem 1999, 34: 81-100.
38. Sinha, U. Synthetic inhibitors of coagulation factor Xa. Exp Opin Invest Drugs 1999, 8: 567-73.
39. Turpie, A.G.G. Pharmacology of the low-molecular weight heparins. Am Heart J 1998, 135: S329-35.
40. Lynch, J.J. Jr., Sitko, G.R., Lehman, E.D., Vlasuk, G.P. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost 1995, 74: 640-5.
41. Nicolini, F.A., Lee, P., Malycky, J.L. et al. Selective inhibition of factor Xa during thromboytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996, 7: 39-48.
42. Ragosta, M., Gimple, L.W., Gertz, S.D. et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral artery in rabbits. Circulation 1994, 89: 1262-71.
43. Maignan, S., Mikol, V. The use of 3D structural data in the design of specific factor Xa inhibitors. Curr Top Med Chem 2001, 1: 161-74.
44. Maignan, S., Guilloteau, J.P., Pouzieux, S. et al. Crystal structures of human factor Xa complexed with potent inhibitors. J Med Chem 2000, 43: 3226-32.
45. Adler, M., Davey, D.D., Phillips, G.B. et al. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochem 2000, 39: 12534-42.
46. Ewing, W.R., Pauls, H.W., Spada, A.P. Progress in the design of inhibitors of coagulation factor Xa. Drugs Fut 1999, 24: 771-87.
47. Roque, M., Reis, E.D., Fuster, V. et al. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Amer Coll Cardiol. 2000, 36: 2303-10.
48. Key, N.S., Bach, R.R. Tissue factor as a therapeutic target. Thromb Hemost 2001, 85: 575-6.
49. Abumiya, T., Enjyoji, K., Kokawa, T., Kamikubo, Y., Kato, H. An antitissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form of TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995, 118: 178-82.
50. Abendschein, D.R., Meng, Y.Y., Torr-Brown, S., Sobel, B.E. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995, 92: 944-9.
51. Oltrona, L., Speidel, C.M., Recchia, D. et al. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997, 96: 646-52.
52. Declerck, P.J., Juhan-Vague, I., Felez, J., Wiman, B. Minisymposium: The role of the fibrinolytic system in the pathophysiology and treatment of thrombosis. J Intern Med 1994, 236: 425-32.
53. Edelberg, J.M., Sane, D.C., Pizzo, S.V. Vascular regulation of plasminogen activator inhibitor-1 activity. Semin Thromb Haemost 1994, 20: 319-23.
54. Charlton, P. Modulators of plasminogen activator inhibitor-1 (PAI-1) activity. Drugs Fut 1997, 22: 45-52.
55. Ciemiewski, C.S., Babinska, A., Swiatkowska, M. et al. Inhibition of modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells. Eur J Biochem 1995, 227: 494-9.
56. Abrahamsson, T., Nerme, V., Stromqvist, M. et al. Antithrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996, 75: 118-26.
57. Bryans, J., Charlton, P., Chicarelli-Robinson, I. et al. Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp. J Antibiot 1996, 49: 1014-21.
58. Woodhouse, P.R., Meade, T.W., Khaw, K.T. Plasminogen activator inhibitor-1, the acute phase response and vitamin C. Atherosclerosis 1997, 133: 71-6.
59. Charlton, P., Faint, R.W., Bent, F. et al. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor activity. Thromb Hemost 1996, 75: 808-15.
60. Lefkovits, J., Plow, E.F., Topol, E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995, 332: 1553-9.
61. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994, 330: 956-61.
62. IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997, 349: 1422-8.
63. Ohman, E.M., Kleiman, N.S., Gacioch, G. et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Circulation 1997, 95: 846-54.
64. PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998, 338: 1498-505.
65. Nicholson, N.S., Abood, N.A., Panzer-Knodle, S.G. et al. Orbofiban: An orally active GPII/IIIa platelet receptor antagonist. Med Res Rev 2001, 21: 211-26.
66. Verstraete, M. Exit of platelet glycoprotein-IIb/IIIa receptor inhibitors? Lancet 2001, 357: 1535.
67. 2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol 1997, 17: 3224-9.
68. 2. Thromb Res 1997, 88: 109-25.
69. 2 synthase inhibitor enhanced antithrombotic efficacy of GP IIb/IIIa receptor antagonist without increased bleeding. Eur J Pharmacol 2001, 417: 217-22.
70. Butenas, S., Cawthern, K.M., van't Veer, C., et al. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001, 97: 2314-22.
71. Schafer, A.I. Antiplatelet therapy. Am J Med 1996, 101: 199-209.
72. Theroux, P. Antiplatelet therapy: Do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J 1997, 134: S62-70.
73. 2 steal" mechanism. Jpn Circ J1986, 50: 1071-8.
74. 2 and thrombin. Thromb Haemost 1994, 71: 366-74.
75. Gaarder, A., Jonsen, J., Laland, S., Hellem, A., Owren, P.A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human platelets. Nature 1961, 192: 531.
76. Born, G.V.R. Quantitative investigations into the aggregation of blood platelets. J Physiol 1962, P67-8.
77. Valles, J., Sanos, M.T., Aznar, J. et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release and recruitment. Blood 1991, 78: 154-62.
78. Daniel, J.L., Dangelmaier, C., Jin, J. et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998, 273: 2024-9.
79. 2 generation in human platelets. Thromb Haemost 82 (Suppl.): 444.
80. Glusa, E., Storey, R.F., Sanderson, H.M., Heptinstall, S. Influence of the ADP antagonists AR-C67085 and A2P5P on ADP-induced responses of platelets and isolated arteries. Thromb Haemost 82 (Suppl.): 166-7.
81. Sugidachi, A., Asai, F., Ogawa, T. et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000, 129: 1439-46.
82. 1-deficient mice. Nat Med 1999, 5: 1199-202.
83. 1 receptor in tissue factor-induced thrombin independent acute thromboembolism. Circulation 2001, 103: 718-23.
84. 1 receptor. Mol Pharmacol 1996, 50: 1323-8.
85. 1 receptor antagonist. Eur J Pharmacol 2001, 412: 213-21.
86. Barnett, H.J.M., Eliasziw, M., Meldrum, H.E. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995, 332: 238-48.
87. Marcus, A.J., Broekman, M.J., Drosopoulos, J.H.F. et al. Thromboregulation by endothelial cells. Arterioscler Thromb Vasc Biol 2001, 21: 178-82.
88. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of platelets. Br Med J 1994, 308: 81-106.
89. Patrono, C., Coller, B., Dalen, J.E. et al. Platelet-active drugs: The relationship among dose, effectiveness, and side effects. Chest 1998, 114 (Suppl. 5): 470-88S.
90. Born, G.V.R., Collins, R. Aspirin versus clopidogrel: The wrong question? Lancet 1997, 349: 806-7.
91. Theroux, P. Antithrombotic treatment of acute coronary syndromes. Can J Cardiol 1998, 14E: 6-10E.
92. Geiger J. Inhibitors of platelet signal transduction as antiaggregatory drugs. Exp Opin Invest Drugs 2001, 10: 865-90.
93. Teng, C-M., Wu, C-C., Ko, F-N., Lee, F-Y., Kuo, S-C. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase inhibits platelet rich thrombosis in mice. Eur J Pharmacol 1997, 320: 161-6.
94. Gurevitz, O., Eldar, M., Skutelsky, E. et al. S-Nitroso-derivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. Thromb Haemost 2000, 84: 912-7.
95. Dikshit, M., Kumari, R., Srimal, R.C. Effect of pulmonary thromboembolism on circulating neutrophils in mice. Thromb Res 1992, 66: 133-9.
96. Dikshit, M., Kumari, R., Srimal, R.C. Pulmonary thromboembolism induced alterations in the nitric oxide release from the rat neutrophils. J Pharmacol Exp Ther 1993, 265: 1369-73.
97. Kumari, R., Singh, M.P., Seth, P., Dikshit, M. Inhibition of platelet aggregation by a protein factor present in the rat peripheral neutrophil supernatant. Thromb Res 1998, 91: 75-82.
98. Axelrod, D.A., Wakefield, T.W. Future directions in antithrombotic therapy: Emphasis on venous thromboembolism. J Am Coll Surg 2001, 192: 5: 641-51.
99. Kumar, A., Villani, M.P., Patel, U.K. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents occlusion in a porcine model. Circulation 1999, 99: 1363-9.
100. Clemetson, K.J., Clemetson, J.M. Platelet collagen receptors. Thromb Haemost 2001, 86: 189-97.
101. Clemetson, J.M., Polgar, J., Magnenat, E., Wells, T.N., Clemetson, K.J. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcαR and the natural killer receptors. J Biol Chem 1999, 274: 29019-24.
102. Cauwenberghs, N., Meiring, N., Vautorin, S. et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000, 20: 1347-53.
103. Yao, S.K., Ober, J.C., Garfinkel, L.I. et al. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis and delays coronary artery occlusion in dogs. Circulation 1994, 89: 2822-8.
104. Kurz, K.D., Smith, T., Moore, R.A., Main, B.W. Comparison of thrombin inhibitors in rat models of thrombosis and thrombolysis. FASEB J 1991, 6: A520.
105. Duval, N., Lunven, C., O'Brien, D.P. et al. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: Comparison with heparin. Br J Pharmacol 1996, 118: 727-33.
106. Thomas, D.P. Venous thrombosis and the "Wessler test". Thromb Haemost 1996, 76: 1-4.
107. McClanahan, T.B., Hicks, G.W., Ignasiak, D.P. et al. The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis. J Thromb Thrombolysis 2000, 10: 277-84.
108. Sato, K., Taniuchi, Y., Kawasaki, T. et al. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 1998, 347: 231-6.
109. Hayashi, M., Matsuo, A., Nakamoto, H., Aisaka, K. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals. Eur J Pharmacol 2001, 412: 61-6.
110. Badimon, L. Models to study thrombotic disorders. Thromb Haemost 1997, 78: 667-71.
111. Horisawa, S., Kaneko M., Ikeda, Y., Ueki, Y., Sakurama, T. Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs. Thromb Res 1999, 94: 227-34.
112. Kurz, K.D., Main, B.W., Sandusky, G.E. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990, 60: 269-80.
113. Romson, J.L., Haack, D.W., Lucchesi, B.R. Electrical induction of coronary artery thrombosis in the ambulatory canine: A model for in vivo evaluation of antithrombotic agents. Thromb Res 1980, 17: 841-53.
114. Mousa, S.A., De Grado, W.F., Mu, D.X. et al. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GP IIb/IIIa antagonist. Circulation 1996, 93: 537-43.
115. Folts, J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991, 83 (Suppl. A): 185A.
116. Mousa, S.A., Mu, D.X., Lucchesi, B.R. Prevention of carotid artery thrombosis by oral platelet GP IIb/IIIa antagonist in dogs. Stroke 1997, 28: 830-6.
117. Cook, J.J., Hoahan, M.A., Lyle, E.A. et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther 1996, 278: 62-73.
118. Wallace, J., Muscara, M.N., McKnight, W. et al. In vivo antithrombotic effects of a nitric oxide-releasing derivative, NCX4016. Thromb Res 1999, 93: 43-50.
119. Momi, S., Emerson, M., Paul, W. et al. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur J Pharmacol 2000, 397: 177-85.
120. Huang, J., Driscoll, E.M., Gonzales, M.L. et al. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931 MX in a canine model. J Pharmacol Exp Ther 2000, 295: 492-9.